Pharmaceuticals

In-Depth Non-injectable Insulin Market Report: Business Trends, Growth Factors, and Forecast to 2029

September 1, 2025 by Marketing Posting

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Does the Forecast Indicate for the Non-injectable Insulin Market From 2025 to 2029?#_x000D_

The market size for obeticholic acid has experienced quick expansion in the past few years. Predicted to increase from $0.9 billion in 2024 to $1.01 billion in 2025, it is expected to have a compound annual growth rate (CAGR) of 12.3%. This escalating market growth during the historical period can be associated with the growing cases of primary biliary cholangitis (PBC), an increase in the rate of non-alcoholic steatohepatitis (NASH), the ongoing expansion of healthcare infrastructure in developing markets, augmented liver disease diagnostics and screening, increasing healthcare spending, and significant investments in liver disease research._x000D_

_x000D_

In the coming years, the market size of obeticholic acid is projected to experience swift expansion, with an expectation to reach “$1.64 billion in 2029, growing at a CAGR of 12.8%. This market growth in the forecast period can be credited to the rising prevalence of disorders such as primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH), the escalating demand for novel liver disease treatments, increased awareness about liver diseases and their available treatments, wider access to healthcare in developing markets, and heightened consciousness about liver ailments and possible remedies. The forecast period is also likely to see trends such as a shift towards NAFLD treatment, greater reliance on digital health tools for tracking and compliance, technological advances in liver disease biomarkers and diagnostic techniques, and an increasing uptake of obeticholic acid for NASH treatment, coupled with more collaborations and partnerships for further progress._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=22079&type=smp_x000D_

_x000D_

#What Elements Are Contributing To Growth In The Non-injectable Insulin Market?#_x000D_

The escalating problems of obesity and diabetes are anticipated to fuel the expansion of the non-injectable insulin market. Obesity, marked by an abnormal pile-up of body fat due to an imbalance in energy consumption and expenditure, and diabetes mellitus, commonly known as diabetes and distinguished by prolonged periods of high blood sugar levels, are two conditions that increasingly warrant the use of non-injectable insulin. This form of insulin is utilized in the treatment of diabetes and obesity and has the capacity to augment disease management by overcoming obstacles to insulin therapy, providing potential weight management benefits, and supplying more user-friendly treatment alternatives. For example, the World Heart Federation, a non-governmental organization based in Switzerland, projected in 2022 a steep rise in global obesity rates. An estimation reveals that 2.3 billion people, including children and adults, struggled with overweight and obesity issues in 2021, but this figure is expected to escalate to 2.7 billion by 2025. Moreover, a report released by the British Diabetic Association, a diabetes charity based in the UK, revealed in April 2023 that 4.3 million people in the UK have diabetes and over 2.4 million UK residents are at a high risk of developing type 2 diabetes. The 2021-22 registration data shows an increase of 148,951 compared to the past year. This surge in obesity and diabetes thus stands as the driving factor for the expansion of the non-injectable insulin market._x000D_

_x000D_

The obeticholic acid market covered in this report is segmented – _x000D_

_x000D_

1) By Product Type: Tablets, Capsules, Other Product Types_x000D_

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_

3) By Application: Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

_x000D_

1) By Tablets: Immediate-Release Tablets, Extended-Release Tablets_x000D_

2) By Capsules: Soft Gelatin Capsules, Hard Gelatin Capsules_x000D_

3) By Other Product Types: Oral Suspensions, Injectable Formulations_x000D_

_x000D_

#What Upcoming Trends Are Expected To Impact The Non-injectable Insulin Market Globally?#_x000D_

Leading firms in the obeticholic acid market are focused on the production of innovative products, such as the farnesoid X receptor (FXR) agonist, with the aim of enhancing treatment for liver disease and improving patient prognosis. A farnesoid X receptor (FXR) agonist is a compound that triggers the activation of the FXR, a nuclear receptor playing a crucial role in the regulation of bile acid metabolism, inflammation, and fibrosis in the liver. Farnesoid X receptor (FXR) agonists contribute to the improved functionality of the liver, and are utilized in treating diseases like primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). In February 2024, a milestone was reached when Intercept Pharmaceuticals Inc., an American biopharmaceutical company, revealed that the U.S. Food and Drug Administration (FDA) had given approval to its supplemental New Drug Application (sNDA) for the use of Ocaliva in the treatment of individuals with primary biliary cholangitis (PBC). The FDA’s approval of the supplemental New Drug Application (sNDA) for obeticholic acid (Ocaliva) marks a significant regulatory step towards the affirmation of its clinical advantages in the treatment of PBC._x000D_

_x000D_

#Who Are The Key Contributors To Growth In The Non-injectable Insulin Market?#_x000D_

Major companies operating in the obeticholic acid market are Pfizer Inc., GlaxoSmithKline (GSK), Gilead Sciences Inc., Amgen Inc., Genfit, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, WuXi AppTec, Bayer AG, Sumitomo Dainippon Pharma Co. Ltd., Horizon Therapeutics, Dr. Reddy’s Laboratories, Lupin Limited, Hepalink Pharmaceutical Group5, Alembic Pharmaceuticals, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals, Viva Life sciences, Omgene Life Sciences Pvt. Ltd., Zydus Cadila _x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/obeticholic-acid-global-market-report_x000D_

_x000D_

#Which Region Is Projected To Lead The Non-injectable Insulin Market By 2025?#_x000D_

North America was the largest region in the Obeticholic Acid market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the obeticholic acid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=22079&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_